Seegene launches Global Million Clinical Study
July 10, 2026—Seegene has launched the Global Million Clinical Study, which aims to evaluate the clinical utility and potential impact of syndromic PCR testing using real-world data.
Webinars and Commercial Conversations — Register Now
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
FDA clears Visby’s at-home multiviral PCR test
July 9, 2026—The FDA has cleared the Visby Medical Flu and COVID-19 at-home PCR test.
Bio-Rad launches Vericheck ddPCR kits for QX700 platform
July 7, 2026—Bio-Rad Laboratories launched its QX700 system-compatible Vericheck ddPCR kit portfolio for quality control workflows in advanced cell and gene therapy development and other biopharma applications.
Epredia launches SlideMate thermal slide printer
July 6, 2026—Epredia has launched sales of the SlideMate thermal slide printer, engineered to help clinical laboratories protect tissue samples, strengthen sample traceability, and streamline workflow efficiency during cancer diagnosis.
Versant expands collaboration with Leica Biosystems
June 30, 2026—Leica Biosystems and Versant Diagnostics are expanding their collaboration to advance digital pathology adoption.
Roche launches Axelios 1 NGS platform
June 29, 2026—Roche has launched the Axelios 1, a next‑generation single-molecule sequencing platform powered by proprietary sequencing by expansion technology.
Thermo Fisher launches LabLink 360 QA software
June 26, 2026—Thermo Fisher Scientific has launched the Thermo Scientific LabLink 360 Quality Assurance software, designed to help clinical laboratories simplify quality control workflows, accelerate QC review and decision-making, improve visibility into QC performance, and manage QC operations.
Merck to acquire Bio-Techne for $11.3 billion
June 25, 2026—Merck (Darmstadt, Germany) has entered into a definitive agreement to acquire Minneapolis-based Bio-Techne Corp. for approximately $11.3 billion.
FDA-approved, at-home ColoSense test now available
June 24, 2026—Labcorp announced that ColoSense, an FDA-approved, at-home test for colorectal cancer screening, is now available for adults ages 45 to 85 who are at average risk for developing CRC.
Liaison Nes group A strep assay gets FDA clearance, CLIA waiver
June 23, 2026—Diasorin has received 510(k) clearance and CLIA waiver from the U.S. Food and Drug Administration for its group A streptococcus assay, for use on the Liaison Nes point-of-care molecular diagnostics platform.